The Institute of Cancer Research
@icr.ac.uk
The ICR is making the discoveries that defeat cancer.
We're a top UK academic research centre, a postgrad college, and a charity.
📍 London (Chelsea and Sutton)
https://www.icr.ac.uk/
We're a top UK academic research centre, a postgrad college, and a charity.
📍 London (Chelsea and Sutton)
https://www.icr.ac.uk/
🚨 Our scientists have been at the forefront of #ProstateCancer screening and drug development for decades – leading innovative research and international clinical trials to give every man with prostate cancer the best chance of survival with a better quality of life.
🧵⬇️
🧵⬇️
November 14, 2025 at 1:27 PM
🚨 Our scientists have been at the forefront of #ProstateCancer screening and drug development for decades – leading innovative research and international clinical trials to give every man with prostate cancer the best chance of survival with a better quality of life.
🧵⬇️
🧵⬇️
It's 25 years of the @breastcancernow.bsky.social Toby Robins Research Centre at the ICR, celebrating the pioneering research that’s transforming the outlook for people with #BreastCancer 🩷
November 13, 2025 at 2:25 PM
It's 25 years of the @breastcancernow.bsky.social Toby Robins Research Centre at the ICR, celebrating the pioneering research that’s transforming the outlook for people with #BreastCancer 🩷
Why do men tend to fare worse than women in acute myeloid leukaemia (AML)?
New research has ruled out hormone signalling as the cause – helping refine the search for biological factors that drive this difference.
A thread 🧵⬇️
New research has ruled out hormone signalling as the cause – helping refine the search for biological factors that drive this difference.
A thread 🧵⬇️
November 11, 2025 at 10:24 AM
Why do men tend to fare worse than women in acute myeloid leukaemia (AML)?
New research has ruled out hormone signalling as the cause – helping refine the search for biological factors that drive this difference.
A thread 🧵⬇️
New research has ruled out hormone signalling as the cause – helping refine the search for biological factors that drive this difference.
A thread 🧵⬇️
A pioneering clinical trial has shown that combining two existing treatments could transform outcomes for people with advanced sarcoma and melanoma in their limbs, providing hope to patients whose treatment options are currently limited.
November 7, 2025 at 9:56 AM
A pioneering clinical trial has shown that combining two existing treatments could transform outcomes for people with advanced sarcoma and melanoma in their limbs, providing hope to patients whose treatment options are currently limited.
🚨In our latest technology feature, we go behind the scenes of the Structural Chemistry Facility at the Centre for Cancer Drug Discovery to explore how mass spectrometry and nuclear magnetic resonance are driving forward the discovery of new cancer treatments.
November 6, 2025 at 9:37 AM
🚨In our latest technology feature, we go behind the scenes of the Structural Chemistry Facility at the Centre for Cancer Drug Discovery to explore how mass spectrometry and nuclear magnetic resonance are driving forward the discovery of new cancer treatments.
BRCA gene testing can identify cancer risk, but access is limited.
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
Could expanding BRCA gene testing save lives in breast and ovarian cancer?
Could expanding BRCA gene testing save lives in breast and ovarian cancer?
www.icr.ac.uk
October 28, 2025 at 9:17 AM
BRCA gene testing can identify cancer risk, but access is limited.
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
A new digital pathway from the ICR is expanding testing in high-risk groups by making the process more efficient and cost-effective.
In the longer term, this approach could lead to better patient outcomes.
More from us here ⬇️
🎉 We were honoured to award Sir Bob Champion CBE with an honorary doctorate for his outstanding work in supporting research into male cancers at our graduation today.
October 27, 2025 at 7:30 PM
🎉 We were honoured to award Sir Bob Champion CBE with an honorary doctorate for his outstanding work in supporting research into male cancers at our graduation today.
Graduation Day is here! 🎓🎓🎓
A huge congratulations to our graduates, ICR fellows, and ICR associates!
Today, we celebrate you and your hard work, dedication, and passion for cancer research.
We’re so incredibly proud of you ✨✨✨✨
Thank you for being such a special part of our community ❤️
A huge congratulations to our graduates, ICR fellows, and ICR associates!
Today, we celebrate you and your hard work, dedication, and passion for cancer research.
We’re so incredibly proud of you ✨✨✨✨
Thank you for being such a special part of our community ❤️
October 27, 2025 at 4:43 PM
Graduation Day is here! 🎓🎓🎓
A huge congratulations to our graduates, ICR fellows, and ICR associates!
Today, we celebrate you and your hard work, dedication, and passion for cancer research.
We’re so incredibly proud of you ✨✨✨✨
Thank you for being such a special part of our community ❤️
A huge congratulations to our graduates, ICR fellows, and ICR associates!
Today, we celebrate you and your hard work, dedication, and passion for cancer research.
We’re so incredibly proud of you ✨✨✨✨
Thank you for being such a special part of our community ❤️
“Although drug resistance closes some doors, it can open new ones.”
In exciting research, our scientists have found that a recently discovered vulnerability in soft tissue sarcomas could pave the way for smarter, more adaptive treatment strategies that extend and save more lives.
In exciting research, our scientists have found that a recently discovered vulnerability in soft tissue sarcomas could pave the way for smarter, more adaptive treatment strategies that extend and save more lives.
October 23, 2025 at 9:34 AM
“Although drug resistance closes some doors, it can open new ones.”
In exciting research, our scientists have found that a recently discovered vulnerability in soft tissue sarcomas could pave the way for smarter, more adaptive treatment strategies that extend and save more lives.
In exciting research, our scientists have found that a recently discovered vulnerability in soft tissue sarcomas could pave the way for smarter, more adaptive treatment strategies that extend and save more lives.
📢 Interested in doing a #PhD with us?
Applications are now open for our 2025/26 fully-funded PhD studentships 🔬 🥼
Subject areas include:
✅Chemistry
✅Biology
✅Computer Science
✅Physics
⚠️ Deadline: Sunday 16 November 2025
Find out more about entry requirements, stipends, and project proposals ⤵️
Applications are now open for our 2025/26 fully-funded PhD studentships 🔬 🥼
Subject areas include:
✅Chemistry
✅Biology
✅Computer Science
✅Physics
⚠️ Deadline: Sunday 16 November 2025
Find out more about entry requirements, stipends, and project proposals ⤵️
Our PhD projects - The Institute of Cancer Research, London
Apply for our fully-funded PhD projects in subjects including chemistry, biology, computer science, and physics.
www.icr.ac.uk
October 22, 2025 at 4:04 PM
📢 Interested in doing a #PhD with us?
Applications are now open for our 2025/26 fully-funded PhD studentships 🔬 🥼
Subject areas include:
✅Chemistry
✅Biology
✅Computer Science
✅Physics
⚠️ Deadline: Sunday 16 November 2025
Find out more about entry requirements, stipends, and project proposals ⤵️
Applications are now open for our 2025/26 fully-funded PhD studentships 🔬 🥼
Subject areas include:
✅Chemistry
✅Biology
✅Computer Science
✅Physics
⚠️ Deadline: Sunday 16 November 2025
Find out more about entry requirements, stipends, and project proposals ⤵️
New global study busts the myth of a ‘cancer epidemic’ in young adults — except for #BowelCancer.
📈 ICR Researchers analysed data from 42 countries and found rising cancer rates in both younger and older adults for several types — not just the under 50s.
📈 ICR Researchers analysed data from 42 countries and found rising cancer rates in both younger and older adults for several types — not just the under 50s.
October 21, 2025 at 8:05 AM
New global study busts the myth of a ‘cancer epidemic’ in young adults — except for #BowelCancer.
📈 ICR Researchers analysed data from 42 countries and found rising cancer rates in both younger and older adults for several types — not just the under 50s.
📈 ICR Researchers analysed data from 42 countries and found rising cancer rates in both younger and older adults for several types — not just the under 50s.
📈This #WorldStatisticsDay, we’re celebrating our statisticians who apply rigorous statistical methods to turn complex data into the discoveries that defeat cancer.
October 20, 2025 at 9:21 AM
📈This #WorldStatisticsDay, we’re celebrating our statisticians who apply rigorous statistical methods to turn complex data into the discoveries that defeat cancer.
Reposted by The Institute of Cancer Research
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks.
Head and neck cancer is the world’s sixth most common form of the disease. If it spreads or comes back after standard treatment, patients may be offered immunotherapy and platinum chemotherapy. But if this fails, there is often little else doctors can do. Continue reading...
www.theguardian.com
October 19, 2025 at 3:39 PM
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
🚨 A new treatment is showing real promise for head & neck cancer.
#Amivantamab shrank or halted tumours in 76 per cent of patients in a new trial presented at @myesmo.bsky.social by ICR's Professor Kevin Harrington and The Royal Marsden.
#ESMO25 #CancerResearch
#Amivantamab shrank or halted tumours in 76 per cent of patients in a new trial presented at @myesmo.bsky.social by ICR's Professor Kevin Harrington and The Royal Marsden.
#ESMO25 #CancerResearch
‘Smart jab’ shows promise in treating advanced head and neck cancer
‘Smart jab’ shows promise in treating advanced head and neck cancer
www.icr.ac.uk
October 19, 2025 at 3:32 PM
🚨 A new treatment is showing real promise for head & neck cancer.
#Amivantamab shrank or halted tumours in 76 per cent of patients in a new trial presented at @myesmo.bsky.social by ICR's Professor Kevin Harrington and The Royal Marsden.
#ESMO25 #CancerResearch
#Amivantamab shrank or halted tumours in 76 per cent of patients in a new trial presented at @myesmo.bsky.social by ICR's Professor Kevin Harrington and The Royal Marsden.
#ESMO25 #CancerResearch
🚨Big news from #ESMO2025 (@myesmo.bsky.social)
A simple MRI scan before bladder cancer surgery could save lives. The BladderPath trial shows fewer delays, fewer deaths, and fewer unnecessary procedures — all from adding one scan at the start.
A simple MRI scan before bladder cancer surgery could save lives. The BladderPath trial shows fewer delays, fewer deaths, and fewer unnecessary procedures — all from adding one scan at the start.
October 17, 2025 at 3:53 PM
🚨Big news from #ESMO2025 (@myesmo.bsky.social)
A simple MRI scan before bladder cancer surgery could save lives. The BladderPath trial shows fewer delays, fewer deaths, and fewer unnecessary procedures — all from adding one scan at the start.
A simple MRI scan before bladder cancer surgery could save lives. The BladderPath trial shows fewer delays, fewer deaths, and fewer unnecessary procedures — all from adding one scan at the start.
Men with BRCA1 and BRCA2 mutations should get annual #ProstateCancer screening.
The IMPACT trial finds BRCA1 carriers are 3 times more likely to have aggressive prostate cancers than non-carriers.
Results from the international trial shared at @myesmo.bsky.social
www.icr.ac.uk/about-us/icr...
The IMPACT trial finds BRCA1 carriers are 3 times more likely to have aggressive prostate cancers than non-carriers.
Results from the international trial shared at @myesmo.bsky.social
www.icr.ac.uk/about-us/icr...
October 17, 2025 at 8:05 AM
Men with BRCA1 and BRCA2 mutations should get annual #ProstateCancer screening.
The IMPACT trial finds BRCA1 carriers are 3 times more likely to have aggressive prostate cancers than non-carriers.
Results from the international trial shared at @myesmo.bsky.social
www.icr.ac.uk/about-us/icr...
The IMPACT trial finds BRCA1 carriers are 3 times more likely to have aggressive prostate cancers than non-carriers.
Results from the international trial shared at @myesmo.bsky.social
www.icr.ac.uk/about-us/icr...
NEWS 📰: New drug combination could tackle advanced #ProstateCancer
40% of advanced prostate cancer patients could be treated with a combination of 2 drugs. The drugs are already in use or in trials to treat cancer.
Read more about the work published in
@natcomms.nature.com ⬇️
40% of advanced prostate cancer patients could be treated with a combination of 2 drugs. The drugs are already in use or in trials to treat cancer.
Read more about the work published in
@natcomms.nature.com ⬇️
New drug combination to tackle advanced prostate cancer
New drug combination to tackle advanced prostate cancer
www.icr.ac.uk
October 15, 2025 at 9:13 AM
NEWS 📰: New drug combination could tackle advanced #ProstateCancer
40% of advanced prostate cancer patients could be treated with a combination of 2 drugs. The drugs are already in use or in trials to treat cancer.
Read more about the work published in
@natcomms.nature.com ⬇️
40% of advanced prostate cancer patients could be treated with a combination of 2 drugs. The drugs are already in use or in trials to treat cancer.
Read more about the work published in
@natcomms.nature.com ⬇️
Big step forward in #BloodCancer care 🚨
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
October 13, 2025 at 8:43 AM
Big step forward in #BloodCancer care 🚨
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
ICR scientists found that combining DNA + RNA tests predicts early relapse in multiple myeloma far better than DNA alone — catching 84% of cases. The Royal Marsden will offer RNA testing from 2026.
Earlier diagnosis = better treatment plans & outcomes.
We were thrilled to welcome @andrewranger-mp.bsky.social and Lesley Griffiths MS to the Wrexham #TerryFox Run! 🏃
It is fantastic to have support from Parliament and the Senedd for a brilliant event honouring Terry’s legacy whilst also raising vital funds for our life-changing cancer research.
It is fantastic to have support from Parliament and the Senedd for a brilliant event honouring Terry’s legacy whilst also raising vital funds for our life-changing cancer research.
October 9, 2025 at 10:28 AM
We were thrilled to welcome @andrewranger-mp.bsky.social and Lesley Griffiths MS to the Wrexham #TerryFox Run! 🏃
It is fantastic to have support from Parliament and the Senedd for a brilliant event honouring Terry’s legacy whilst also raising vital funds for our life-changing cancer research.
It is fantastic to have support from Parliament and the Senedd for a brilliant event honouring Terry’s legacy whilst also raising vital funds for our life-changing cancer research.
We're proud to have received an #AthenaSwan Silver Award from @advancehe.bsky.social for another four years.
The award recognises our continued progress in embedding gender equality and fostering an inclusive research culture.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
#ALD25
The award recognises our continued progress in embedding gender equality and fostering an inclusive research culture.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
#ALD25
Athena Swan Silver renewal recognises ICR’s continued progress in fostering an inclusive research culture
Athena Swan Silver renewal recognises ICR’s continued progress in fostering an inclusive research culture
www.icr.ac.uk
October 8, 2025 at 1:29 PM
We're proud to have received an #AthenaSwan Silver Award from @advancehe.bsky.social for another four years.
The award recognises our continued progress in embedding gender equality and fostering an inclusive research culture.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
#ALD25
The award recognises our continued progress in embedding gender equality and fostering an inclusive research culture.
Read more ⤵️
www.icr.ac.uk/about-us/icr...
#ALD25
New hope for people living with #PancreaticCancer
Researchers have found that a combination of two existing experimental treatments is much more effective than either treatment alone.
They also identified a new cancer-causing mechanism that limits treatment effectiveness.
Researchers have found that a combination of two existing experimental treatments is much more effective than either treatment alone.
They also identified a new cancer-causing mechanism that limits treatment effectiveness.
October 8, 2025 at 8:57 AM
New hope for people living with #PancreaticCancer
Researchers have found that a combination of two existing experimental treatments is much more effective than either treatment alone.
They also identified a new cancer-causing mechanism that limits treatment effectiveness.
Researchers have found that a combination of two existing experimental treatments is much more effective than either treatment alone.
They also identified a new cancer-causing mechanism that limits treatment effectiveness.
🔬 A new study, led by @udaibanerji.bsky.social, reveals a fast, low-cost solution for harvesting #organoids.
These miniature 3D models of human tissue mimic the behaviour of real tumours and are considered the future of #CancerResearch.
Read more in our 🧵⤵️
#Oncology
These miniature 3D models of human tissue mimic the behaviour of real tumours and are considered the future of #CancerResearch.
Read more in our 🧵⤵️
#Oncology
October 1, 2025 at 9:13 AM
🔬 A new study, led by @udaibanerji.bsky.social, reveals a fast, low-cost solution for harvesting #organoids.
These miniature 3D models of human tissue mimic the behaviour of real tumours and are considered the future of #CancerResearch.
Read more in our 🧵⤵️
#Oncology
These miniature 3D models of human tissue mimic the behaviour of real tumours and are considered the future of #CancerResearch.
Read more in our 🧵⤵️
#Oncology
The Breast Health campaign is live—featuring insights from the ICR on how science could help predict who’s most at risk of #BreastCancer.
Read it online or in today’s @theguardian.com ⬇️
Read it online or in today’s @theguardian.com ⬇️
Could science predict who will get breast cancer?
For over two decades, a team of scientists have been quietly transforming our understanding of breast cancer. The Breast Cancer Now Generations Study, launched in 2004 and led by scientists at The Ins...
www.healthawareness.co.uk
September 30, 2025 at 8:54 AM
The Breast Health campaign is live—featuring insights from the ICR on how science could help predict who’s most at risk of #BreastCancer.
Read it online or in today’s @theguardian.com ⬇️
Read it online or in today’s @theguardian.com ⬇️
🚨 Big news from the TORPEdO trial
IMRT is just as effective as proton beam therapy for most head and neck cancer patients.
That means more people can access the best treatment locally—without needing specialist centres.
Learn more here ⬇️
www.icr.ac.uk/about-us/icr...
IMRT is just as effective as proton beam therapy for most head and neck cancer patients.
That means more people can access the best treatment locally—without needing specialist centres.
Learn more here ⬇️
www.icr.ac.uk/about-us/icr...
September 29, 2025 at 6:11 PM
🚨 Big news from the TORPEdO trial
IMRT is just as effective as proton beam therapy for most head and neck cancer patients.
That means more people can access the best treatment locally—without needing specialist centres.
Learn more here ⬇️
www.icr.ac.uk/about-us/icr...
IMRT is just as effective as proton beam therapy for most head and neck cancer patients.
That means more people can access the best treatment locally—without needing specialist centres.
Learn more here ⬇️
www.icr.ac.uk/about-us/icr...
By focusing research on either ‘adult cancer’ or ‘childhood cancer’, we risk excluding teenagers and young adults (TYA). We need to treat TYA patients as a distinct subpopulation that straddles paediatric and adult cancer services.
September 29, 2025 at 12:04 PM
By focusing research on either ‘adult cancer’ or ‘childhood cancer’, we risk excluding teenagers and young adults (TYA). We need to treat TYA patients as a distinct subpopulation that straddles paediatric and adult cancer services.